ubs raises abbott price target to 146 maintaining buy rating

Abbott's price target has been increased by UBS to $146, with a Buy rating on the shares. The firm attributes Abbott's modest sales and earnings per share (EPS) beats as a key factor in boosting confidence in the company's potential for double-digit growth in its MedTech segment in the future, along with high single-digit growth in total sales.

UBS analysts believe that the market is currently undervaluing the sustainability of Abbott's MedTech business growth trajectory. They view Abbott as a top-tier opportunity for investors seeking consistent sales growth in the high single-digit to low double-digit range.

Trending
Subcategory:
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings